TPTX - TPTX STOCK NEWS

Turning Point Therapeutics (NASDAQ: TPTX) has appointed Paolo Tombesi as the new executive vice president and CFO, starting July 26. Tombesi brings 30 years of experience from his previous roles in biotech, including as CFO of Epizyme, Inc., where he facilitated the launch of Tazverik. The company aims to strengthen its finance organization ahead of the potential launch of repotrectinib, a leading cancer therapy in development. Tombesi expressed enthusiasm about joining the team and contributing to the company's growth and commercialization efforts.

Turning Point Therapeutics (NASDAQ: TPTX) announced that its MET inhibitor, TPX-0022, has received orphan drug designation from the FDA for treating gastric cancer, including gastroesophageal junction adenocarcinoma. This designation aims to facilitate the development of drugs for rare diseases with fewer than 200,000 patients annually. Currently, there are no approved MET inhibitors for gastric cancer. Initial Phase 1 data indicated TPX-0022's potential effectiveness and tolerability in MET-driven gastric cancer patients.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) announced that President and CEO Athena Countouriotis, M.D., will participate in a Q&A session at the 42nd annual Goldman Sachs Healthcare Conference on June 9 at 1:20 p.m. ET. The session will be accessible via audio webcast on the company’s Investor page. Turning Point focuses on precision oncology, with investigational drugs targeting genetic drivers of cancer, including their lead candidate repotrectinib, currently in multiple clinical trials.

Turning Point Therapeutics (NASDAQ: TPTX) appointed Mark Alles, former Celgene chairman and CEO, as chair of its board of directors, succeeding Garry Nicholson, who remains on the board. Alles brings over 30 years of biopharmaceutical experience, having expanded Celgene significantly prior to its $74 billion acquisition by Bristol Myers Squibb in 2019. Under his leadership, Turning Point aims to advance its clinical-stage drug candidates, particularly repotrectinib, as they prepare for possible registration and commercialization, enhancing their oncology-focused pipeline.

Turning Point Therapeutics (NASDAQ: TPTX) has appointed Kumar Srinivasan, Ph.D., MBA, as executive vice president and chief business officer, effective June 1, 2021. With over 20 years of experience in the pharmaceutical sector, Dr. Srinivasan previously led global business development at AstraZeneca. His role will focus on corporate strategy and collaborations as TPTX advances its pipeline of four clinical stage drug candidates. The company's lead candidate, repotrectinib, targets specific genetic drivers in cancer and is undergoing significant clinical trials, highlighting TPTX's commitment to precision oncology.

Turning Point Therapeutics (TPTX) reported significant achievements during Q1 2021, including a completed Type B FDA meeting regarding repotrectinib for ROS1-positive NSCLC. The company expects to discuss topline results in Q1 2022. They received IND approval for combining repotrectinib with trametinib in KRAS-driven tumors and initiated multiple clinical studies. Q1 revenue was $25.2 million, while R&D expenses increased to $41.3 million. The net loss was $35.5 million, with cash reserves of $1.1 billion projecting operational funding through 2024.

Turning Point Therapeutics (NASDAQ: TPTX) will release its Q1 financial results on May 5, 2021, post U.S. market close. A conference call led by President and CEO Athena Countouriotis, M.D., is scheduled for 2:00 p.m. PT / 5:00 p.m. ET to discuss the results and provide updates. Interested parties can access the call via audio webcast or by calling (877) 388-2118 (U.S.) or (470) 495-9489 (international) using conference ID 7397513. Turning Point is focused on developing precision oncology therapies targeting genetic drivers of cancer, with key products in clinical trials.

Turning Point Therapeutics (TPTX) has announced the initiation of its Phase 1/2 FORGE-1 study for TPX-0131, a novel inhibitor targeting ALK mutations. This marks the company’s third FDA-cleared investigational new drug (IND) application in under two years and fourth clinical study launched in the same timeframe. The study commenced in Australia, with plans for U.S. site activation. The trial focuses on patients with advanced ALK-positive non-small cell lung cancer (NSCLC) who have had limited options. TPX-0131 aims to provide a potent alternative against resistance mutations.

Turning Point Therapeutics (TPTX) has announced new preclinical data supporting the development of its drug candidates, repotrectinib, TPX-0022, and TPX-0131, to be presented at the AACR annual meeting held virtually from April 9-14, 2021. The data for repotrectinib indicates enhanced efficacy in conjunction with MEK inhibitors against KRAS mutant cancers. Additionally, TPX-0022 shows potential as a MET/SRC/CSF1R inhibitor, and TPX-0131 demonstrates potency against ALK mutations. These findings aim to advance their clinical studies, especially the TRIDENT-2 and SHIELD-2 trials.